TECLens, Inc. raised $9.3 million in a Series A funding round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital to advance its non-invasive refractive technology.
TECLens, Inc. raised $9.3 million in a Series A funding round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital to advance its non-invasive refractive technology.
02/11/25, 2:19 PM
Location
stamfordMoney raised
$9.3 million
Industry
health care
Round Type
series a
Investors
Sunmed Capital, Rimonci Capital, Yonjin Capital, Johnson & Johnson Innovation – Jjdc Inc.
TECLens, Inc., a clinical-stage ophthalmic medical device company, announced today it raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital. The funding will support the clinical development of the company’s non-incisional refractive correction procedure.
Company Info
Location
9 riverbend dr s
stamford, connecticut, united states
Additional Info
TECLens is a clinical-stage ophthalmic medical device company, pioneering non-invasive personalized corneal cross-linking technology (qCXL™) for vision correction. Our innovative CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries. TECLens’ breakthrough technology aims to set a new standard in precision, accessibility, and patient experience—redefining vision correction with innovation that improves quality of life.